TD Cowen Raises Price Target for Tandem Diabetes (TNDM) Amid Strategic Shift

On April 20, TD Cowen raised its price target on Tandem Diabetes Care Inc. (NASDAQ:TNDM) from $25 to $28 and maintained a Buy rating due to the company's new pay-as-you-go program and Mobi Tubeless product launch in Q4 2025. The firm anticipates revenue headwinds of $85 million to $95 million globally as Tandem transitions its distribution model over two to three years.

By Ali Ahmed Fri, May 1, 2026 at 12:42 AM GMT+3 2 min read · Yahoo Finance · April 30, 2026, 21:42 UTC

Tickers: $TNDM

Topics: Analyst Rating Diabetes Technology Medical Stocks Revenue Growth

Read the full article at Yahoo Finance

More World news

Federal Reserve to Designate October 2027 Meeting as Non-Voting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Sprott Physical Platinum and Palladium Trust Reports Q3 Net Income Decline Seeking Alpha · November 12, 2026, 17:47 UTC
Nvidia CEO Jensen Huang Resigns Amidst Market Volatility and AI Sector Shifts Motley Fool · November 12, 2026, 17:45 UTC
Honda to Transition CR-V Lineup to All-Hybrid Powertrains by 2027 Seeking Alpha · November 12, 2026, 17:43 UTC
Sprott Physical Silver Trust USD Reports Q3 Net Income of $425.83 Million Seeking Alpha · November 12, 2026, 17:44 UTC
Nvidia CEO Jensen Huang Resigns Amid Allegations of Personal Misconduct and China Export Control Concerns The Verge · November 12, 2026, 17:44 UTC
NYSE Sees $500 Billion in Market Cap Transfers from Competitors in 2026 PR Newswire · November 12, 2026, 17:45 UTC
Hyperion DeFi Reports Record Net Income and Positive Operating Cash Flow in Q3 2026 Motley Fool · November 12, 2026, 17:40 UTC
Suburban Propane Reports Fiscal 2026 Results with Increased Adjusted EBITDA and RNG Growth Motley Fool · November 12, 2026, 17:40 UTC
Altimmune Reports Third Quarter 2026 Financial Results Amid Increased R&D Spending Motley Fool · November 12, 2026, 17:40 UTC